← 返回

结构引导的 TIGIT 工程化改造以调控其与 Nectin-4(一种肿瘤特异性抗原)的相互作用,用于治疗策略的开发

英文原题:Structure-Guided Engineering of TIGIT to Modulate Its Interaction With Nectin-4, a Tumour-Specific Antigen for the Development of Therapeutic Strategy.

查看英文原题

Structure-Guided Engineering of TIGIT to Modulate Its Interaction With Nectin-4, a Tumour-Specific Antigen for the Development of Therapeutic Strategy.

PubMed 2026/04/01(内容时间) Eur J Immunol Q2 · IF 4.1(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

Nectin 和 nectin 样蛋白是属于免疫球蛋白超家族的细胞黏附分子,它们还通过与 TIGIT、DNAM-1、CD96 和 PVRIG 等免疫受体相互作用,在免疫调节过程中发挥关键作用。Nectin-4 是一种肿瘤特异性抗原,它专门与抑制性免疫受体 TIGIT 相互作用,从而抑制 NK 细胞毒性,并促进癌细胞在肿瘤微环境中的免疫逃逸过程。

因此,阐明这种新型相互作用背后的分子和结构机制,可为开发靶向免疫治疗干预措施提供思路。在本研究中,利用结构导向的突变研究,工程化改造出一种新型 TIGIT 突变体,其对 nectin-4 表现出增强的相互作用亲和力,同时与其他 TIGIT 配体(如 PVR 和 nectin-2)的结合降低,而与 nectin-4 不同,这些配体主要表达于健康细胞上。进行了基于表面等离子体共振的生物物理学研究,以表征并比较野生型(WT)和工程化突变体 TIGIT 胞外域与其配体的相互作用动力学。

我们展示了位于 TIGIT F 链中心的一个氨基酸残基的单点突变如何决定其与配体的相互作用亲和力。这些发现可为开发专门靶向 nectin-4 过表达癌细胞、且对健康细胞脱靶效应最小的小型非抗体治疗药物提供框架。

展开英文摘要原文

Nectin and nectin-like proteins are cell adhesion molecules belonging to the immunoglobulin superfamily that also play a crucial role in the process of immune modulation by interacting with immune receptors like TIGIT, DNAM-1, CD96 and PVRIG. Nectin-4 is a tumour-specific antigen that interacts exclusively with the inhibitory immune receptor TIGIT, resulting in inhibition of NK-cell cytotoxicity and facilitating the process of immune evasion by the cancer cells in the tumour microenvironment.

Therefore, deciphering the molecular and structural mechanisms underlying this novel interaction can provide insights for the development of targeted immunotherapeutic interventions. In this study, using structure-guided mutagenesis studies, a novel TIGIT mutant is engineered exhibiting enhanced interaction affinity towards nectin-4 and reduced binding to other TIGIT ligands, such as PVR and nectin-2, which, in contrast to nectin-4, are predominantly expressed on healthy cells.

Surface plasmon resonance-based biophysical studies were done to characterize and compare the interaction kinetics of the wild-type (WT) and the engineered mutant TIGIT ectodomains with their ligands.

We have shown how a single point mutation of an amino acid residue located in the centre of the F strand of TIGIT dictates its interaction affinity with its ligand.

These findings can provide a framework for the development of small-sized non-antibody therapeutics specifically targeted towards nectin-4 overexpressing cancer cells with minimal off-target effects on healthy cells.

论文信息

作者
Ganguli N、Shaw S、Sarkar S、Goswami S、Mukherjee G、Samanta D
单位
Department of Bioscience and Biotechnology, Indian Institute of Technology Kharagpur, Kharagpur, India.India
文献类型
非美国政府资助研究
期刊
European journal of immunology2026 Apr
原文标识
PubMed 41928599 · DOI 10.1002/eji.70179